Active Ingredient History
Amiodarone is an antiarrhythmic with mainly class III properties, but it possesses electrophysiologic characteristics of all four Vaughan Williams classes. Like class I drugs, amiodarone blocks sodium channels at rapid pacing frequencies, and like class II drugs, amiodarone exerts a noncompetitive antisympathetic action. In addition to blocking sodium channels, amiodarone blocks myocardial potassium channels, which contributes to slowing of conduction and prolongation of refractoriness. It is indicated for initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy. The most common adverse reactions (1-2%) leading to discontinuation of intravenous amiodarone therapy are hypotension, asystole/cardiac arrest/pulseless electrical activity, VT, and cardiogenic shock. Other important adverse reactions are, torsade de pointes (TdP), congestive heart failure, and liver function test abnormalities. Fluoroquinolones, macrolide antibiotics, and azoles are known to cause QTc prolongation. There have been reports of QTc prolongation, with or without TdP, in patients taking amiodarone when fluoroquinolones, macrolide antibiotics, or azoles were administered concomitantly. Since amiodarone is a substrate for CYP3A and CYP2C8, drugs/substances that inhibit these isoenzymes may decrease the metabolism and increase serum concentration of amiodarone. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Ablation Techniques (Phase 2)
Amyloidosis (Phase 2)
Atrial Fibrillation (Phase 4)
Atrial Flutter (Phase 3)
Blood Pressure (Phase 2)
Cardiomyopathies (Phase 4)
Cardiomyopathy, Dilated (Phase 4)
Cardiovascular Diseases (Phase 3)
Catheter Ablation (Phase 3)
Chagas Cardiomyopathy (Phase 3)
Coronary Artery Bypass (Phase 4)
Coronary Artery Disease (Phase 3)
COVID-19 (Phase 2/Phase 3)
Death, Sudden (Phase 3)
Death, Sudden, Cardiac (Phase 3)
Defibrillators, Implantable (Phase 3)
Esophageal Neoplasms (Phase 2)
Esophagectomy (Phase 4)
General Surgery (Phase 4)
Healthy Volunteers (Phase 1)
Heart Arrest (Phase 3)
Heart Diseases (Phase 4)
Heart Failure (Phase 4)
Hemorrhagic Fever, Ebola (Phase 2/Phase 3)
Infant, Premature (Phase 4)
Lung Neoplasms (Phase 3)
Lung Transplantation (Phase 2)
Myocardial Infarction (Phase 3)
Postoperative Complications (Phase 4)
Respiratory Insufficiency (Phase 4)
Sepsis (Phase 4)
Shock, Septic (Phase 4)
Stroke (Phase 3)
Tachycardia (Phase 4)
Tachycardia, Supraventricular (Phase 2)
Tachycardia, Ventricular (Phase 4)
Thoracic Surgery (Phase 4)
Ventricular Fibrillation (Phase 4)
Ventricular Premature Complexes (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
